Merck paying $2.75B for cancer therapeutics firm VelosBio November 5, 2020 Auto Bot BioPharma, biopharma nl, KEYTRUDA, Merck, News, Oncology, Startups 0 The deal will broaden Merck’s oncology portfolio as it picks up an antibody-drug conjugate, a class of biological drugs that target tumor cells even as the pharma giant jettisons other parts of its business